Background-Thrombus aspiration during percutaneous coronary intervention (PCI) for the treatment of ST elevation myocardial infarction (STEMI) has been widely used; however, recent trials have questioned its value and safety. In this meta-analysis, we, the trial investigators, aimed to pool the individual patient data from these trials to determine the benefits and risks of thrombus aspiration during PCI in patients with STEMI. Methods-Included were large (N thrombectomy vs. PCI alone in patients with STEMI. Individual patient data was provided by the leadership of each trial. The pre-specified primary efficacy outcome was cardiovascular (CV) mortality within 30 days and the primary safety outcome was stroke or transient ischemic attack (TIA) within 30 days. 
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What is new?
This is an individual patient meta-analysis of more than 18,000 patients with STEMI randomized to thrombus aspiration vs. PCI alone.
As a routine strategy, thrombus aspiration did not reduce in cardiovascular mortality for STEMI patients undergoing primary PCI.
An exploratory analysis of patients with high thrombus burden suggests that thrombus aspiration may improve CV mortality but at the price of an increased risk of stroke or TIA.
What are the clinical implications?
Thrombus aspiration should not be used as a routine strategy in patients with STEMI.
Further larger randomized trials are needed to determine if improved forms of thrombus aspiration can reduce CV mortality and to determine its safety with regards to stroke.
Thrombus aspiration should not be used as a routine strategy in patients w wit ith h h ST ST STEM EM EMI. I. I
Introduction
The optimal treatment for ST elevation myocardial infarction (STEMI) is rapid reperfusion with timely primary percutaneous coronary intervention (PCI) if available. 1 However, one of the limitations of primary PCI is embolization of thrombus distally and microvascular occlusion, associated with markedly increased mortality. 2 Thrombus aspiration was thought to be a simple method to remove thrombus prior to stent deployment, thereby reducing distal embolization and improving outcomes.
Thrombus aspiration became part of routine practice based on the promising results of an early trial. 3, 4 However, the results of more recent, larger, multicenter trials have created uncertainty about the benefit of thrombus aspiration and suggested possible harm from increased stroke risk. [5] [6] [7] [8] [9] None of the individual trials were powered to detect a modest reduction in mortality (e.g. 20%) or of low frequency events such as stroke. Accordingly, we undertook an individual patient level meta-analysis to determine the effect of thrombus aspiration on 30-day cardiovascular mortality and stroke or transient ischemic attack (TIA).
Methods
The meta-analysis was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) guidelines for individual patient data meta-analyses. 10 The protocol was finalized and registered at PROSPERO (international register of systematic reviews, CRD42015025936) and clinicaltrials.gov (NCT02552407) prior to unblinding or any data analysis. Large randomized trials (recruiting 1000 patients or more) that compared manual thrombus aspiration plus PCI and PCI alone in patients with STEMI were eligible. Large randomized trials were only included as small trials are more susceptible to uncertainty about the benefit of thrombus aspiration and suggested possible harm m fr fr rom om om in in ncr cr crea ea eas se s d troke risk.
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None of the individual trials were powered to detect a modest reduction in mortality ( (e.g. 20%) or of low frequency events such as stroke. Accordingly, we undertook an ndi ivi vi vidual patie ie ien nt n l lev e e el el el m m met et e a-an an anal al alys ys ysis t to o determ m mine e the e ef ef effe fe fect ct ct of f th th hro ro r mb mbus u asp sp spir ir i at at atio io ion on on o 3 3 30-0-0 da da day y y card d dio io i vascular r m m mor ort tali ity and nd d stroke or tr transien n nt isch chem m mic ic ic a a att t ttac ack (T TIA). . publication bias and tend to be lower quality. A comprehensive search strategy was used for
Medline, EMBASE and Cochrane Central Register of Controlled Trials on September 2, 2016 with no language restriction (online appendix).
Authors of eligible trials collaboratively shared individual patient level data. The databases from the individual trials were merged into a dedicated SAS file set up for the present study. Data-sets were rigorously reviewed for completeness and consistency to ensure that no errors had occurred in reformatting of the data, and to ensure agreement with the original publications. Any differences were resolved by queries within the collaborative group.
Variables were not defined according to identical criteria in the studies but common definitions were defined by consensus within the author group, whenever possible. Please refer to online supplement for details regarding outcomes variables. The TAPAS trial did not prospectively collect stroke or TIA data and was not included for this outcome. Outcomes were not adjudicated in TASTE and were from discharge diagnoses in administrative databases and death registry.
The risk of bias was assessed as per the Cochrane Collaboration tool (figure S1).
The three individual trials (TASTE, TAPAS and TOTAL) were each approved by an institutional review committee and participants provided informed consent.
Study Organization
All data were merged at the Uppsala Clinical Research Center (UCR), Sweden and analyses were performed using R version 3.2 (R Foundation for Statistical Computing, Vienna, Austria).
Kaplan Meier curves and forest plot figures were created at the Population Health Research Institute (PHRI), Canada using S-PLUS (TIBCO Software Inc, Palo Alto, Ca).
Statistical Analysis
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Th T e th h t ree i indi di i vi id du l al t i rials (T ( AS ASTE T For outcome of stroke or TIA, the exact time of event was not available during initial hospitalization in the TASTE trial so logistic regression was used for significance testing and to calculate odds ratios and 95% CI with treatment group as the predictor variable.
Subgroup Analyses
We hypothesized that thrombus aspiration might be more effective in patients with higher thrombus burden. Accordingly, pre-specified subgroup analyses were performed comparing Thrombolysis In Myocardial Infarction (TIMI) thrombus grade <3 vs. and <4 vs. .
Additional pre-specified subgroup analyses were based on time from symptom onset (<6 vs. inhibitor. Statistical interactions were evaluated at a significance level of 0.05 with no adjustment made for multiple comparisons.
Results
Of the 19,047 patients enrolled in the three randomized trials, 18,306 underwent PCI and were included in the primary analysis ( figure 1 ). The individual trials ( ThrOmbecTomy with PCI versus PCI ALone in Patients with STEMI (TOTAL, N= N= =10 10 1 ,7 ,7 732 32 32) ) ) 7 7 7 .
These three large trials accounted for 19,047 patients out of 22,057 patients enrolled in manual r hrombus aspiration trials.
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Efficacy and Safety
The primary efficacy outcome of cardiovascular death within 30 days in patients who had undergone PCI for STEMI was 2.4% in the thrombus aspiration group, compared with 2.9% in the PCI alone group (hazard ratio 0.84; 95% CI 0.70-1.01, p=0.06 study level interaction p=0.05, Figure 2 , Table 2 ). The primary safety outcome of stroke or TIA at 30 days was 0.8% in the thrombus aspiration group compared with 0.5% in the PCI alone group (odds ratio ratio 1.43; 95% CI 0.98-2.1, p=0.06), but with significant study level interaction p=0.02. There were no statistically significant differences in recurrent myocardial infarction, stent thrombosis or target vessel revascularization (Table 2) . At 1 year, the rate of cardiovascular death was 3.7% in the thrombus aspiration group compared with 4.2% in the PCI alone group (hazard ratio 0.90; 95%
CI 0.78-1.04, p=0.15, Figure 2 ).
Subgroup Findings
In those with thrombus aspiration was associated with reduced cardiovascular death (2.5% vs. 3.1%, hazard ratio 0.80; 95% CI 0.65-0.98, p= 0.03) with no significant heterogeneity across studies (study level interaction p=0.22). However, this subgroup had an excess in stroke or TIA (0.9% vs. 0.5% odds ratio 1.56; 95% CI 1.02-2.42, p= 0.04, Table 3 ) with no significant heterogeneity across studies (study level interaction p=0.09). In the low thrombus burden subgroup (TIMI Thrombus Grade <3), there were no differences in cardiovascular death (2.2% vs. 2.2%, hazard ratio 1.00; 95% CI 0.68-1.47) or in stroke or TIA (0.5% vs. 0.5%, odds ratio 0.99; 95% CI 0.43-2.26). Interaction p-values for differences in cardiovascular death and for stroke or TIA, according to the TIMI thrombus grade 3 cut point were not statistically significant (p = 0.32 and 0.34, respectively, Table 3 ). Table 3 ).
There appeared to be a greater benefit for thrombus aspiration in patients receiving a GP IIb/IIIa inhibitor for cardiovascular death within 30 days (interaction p=0.048) but there was also increased risk of stroke or TIA (interaction p=0.04, Figure 3a and 3b). There appeared to be a potential benefit in patients presenting within 6 hours for CV death but also harm in terms of stroke ( Figure 3a and 3b).
Discussion
In contrast to traditional meta-analyses summarizing group data, the present meta-analysis used individual patient data which provided considerably greater power to examine important but low frequency events such as cardiovascular death and stroke and it allowed the evaluation of specific subgroups such as the one with a high thrombus burden. The protocol was finalized and registered prior to starting the analysis as per the PRISMA guidelines for individual patient data meta-analyses. 10 At 30 days, there were no statistically significant differences for cardiovascular mortality, all-cause mortality between a strategy of routine manual thrombus aspiration vs PCI alone overall.
Although there were no statistically significant subgroup interactions, in the subgroup of patients with high thrombus burden, there was a nominal reduction in CV mortality and in troke (Figure 3a and 3b).
Discussion n c con on ontrast to t t tra ra radi i iti ti ion n nal al al m m met e a a a---an an anal al alys ys y es s su s mmar ar a izin ing gr gr grou ou oup p p da d d ta a, , th h he e pr res e ent t t me me m ta-an an anal al alys ys ysis is is used ed ed individua a al l pa pati ien nt data a a w w which p p provi vided co o on nsid derab ab ably ly ly g g gre rea ater p power er to o o e ex e amin ne e im mp portan nt bu ow f frequency events such h as cardi iovascular d de d ath h h and d strok ke a d nd it al ll lowed d the ev l alua i tion of all-cause mortality but an increase in stroke or TIA at 30 days. It is biologically plausible that thrombus aspiration is only beneficial in patients with moderate to high thrombus burden. On the other hand, if the mechanism of stroke is embolization of thrombus from the coronary artery to systemic circulation, it is logical that the risk would be higher in patients with high thrombus burden. Finally, in patients with high thrombus burden, the increase in stroke could counterbalance an early benefit such that the effect on all-cause mortality at 1 year was neutral.
For stroke or TIA, there was a significant study level interaction. One potential reason is that the TASTE trial randomized patients after angiography while TOTAL and TAPAS did so pre-angiography and so it is possible that angiographic anatomy varied between the studies.
Thrombus burden has been linked to stroke risk and one hypothesis is that TOTAL had a higher stroke risk with thrombus aspiration due to inclusion of patients with a higher thrombus burden. 8 To support this hypothesis, in the subgroup of patients with high thrombus burden, we found consistency at the study level for effect of thrombus aspiration on both CV death and stroke or TIA. However, these results should be interpreted cautiously, given this is a post hoc analysis.
Furthermore, an important limitation is that TAPAS did not collect stroke or TIA and neurologic events were not adjudicated in TASTE.
Limitations of current manual thrombus aspiration technology include thrombus embolization downstream due to wire crossing (prior to aspiration), limited ability to deal with large organized thrombi, and embolization of thrombus to other vascular territories during removal of the aspiration catheter. These limitations are consistent with the TOTAL optical cohence tomography substudy which showed a similar residual thrombus volume after routine thrombus aspiration and after balloon angioplasty. 12 Thrombus burden has been linked to stroke risk and one hypothesis is that TOTA AL L ha ha h d d d a a a hi hi high gh ghe er troke risk with thrombus aspiration due to inclusion of patients with a higher thrombus burden. 8 To support this hypothesis, in the subgroup of patients with high thrombus burden, we found con nsis is istency at t t th h he s s study dy dy l l lev ev e el l f f for or o e e eff ff ffect t of o throm om o bu us as s spi pi pira ra rati ti tion o o o on n n bo bo b th h C CV de de deat at ath h h an a a d st stro ro roke ke ke o o or TIA A. A. Howeve ve ver r, r t th hese resu ul u t ts t should be be interpr pr p eted ed c c cau au auti ti t ou ou o sl s y y, g giv ven t th his s i is i a post t t ho hoc analysi is. This individual patient meta-analysis is novel because it utilized cause-specific mortality (CV mortality) compared to all-cause mortality presented in the original TASTE and TAPAS publications. 3, 11 This is important as cause-specific mortality is more likely to be responsive to the intervention than all-cause mortality and thus increases study power. Furthermore, we pre-specified our primary outcome at 30 days instead of 180 days (primary outcome of TOTAL)
as we hypothesized that the greatest benefit may be early for a one time intervention compared to 20% reduction in cardiovascular mortality based on the event rates observed in thi his s da da d ta ta a--se se et. t. t Th T T e feasibility of such a trial may be questioned, however, the large fibrinolytic trials enrolled similar numbers of patients.
The find nd ndin ng g g th hat at a t t thr hr hrom om mbu bu bus s s as as a pira ration m m may a re educ c ce e e ca ca ard rd rdio ova va asc sc s ul u ar ar mo ort rt rtal al a it it ity y y bu b t in in ncr cr crea ea ease se se tro o oke ke k or TIA in in n tho hose e t treated ed ed with GP IIb/IIIa a a i inh hib bit t tor or ors s s sh sh shou ould b be e inte er rpre re reted caut ut uti ious usly. an ongoing therapy. Finally, we had detailed baseline data and were able to examine the effect of thrombus aspiration on important subgroups based on thrombus burden and time of symptom onset, both factors which may predict benefit of thrombus aspiration.
Limitations of this analysis are related to limitations of the datasets of the individual trials.
The TAPAS did not prospectively collect the outcome of nonfatal stroke and was not included in the stroke analyses. 3 Direct stenting was recommended in TAPAS but not in the other trials.
TASTE collected the composite outcome of stroke or TIA but not stroke alone, necessitating the composite of stroke or TIA as safety outcome in our meta-analysis. 11 The time of stroke or TIA during the initial hospitalization was not collected in TASTE so a time to event analysis was not possible for this outcome. Outcomes in the TASTE trial were from administrative databases, clinical registries and death certificates and were not adjudicated. Another limitation is that thrombus grade was assessed prior to wire crossing in both TAPAS and TOTAL and after wire crossing in TASTE. There was no adjustment for multiple comparisons so all secondary analyses should be considered hypothesis generating. Another limitation is that no adjustment for clustering was performed. Finally, despite nearly 20,000 patients randomized, this analysis still was relatively underpowered to detect a modest but clinically important, 20% relative risk reduction in cardiovascular mortality within 30 days.
Conclusions
Routine manual thrombus aspiration during STEMI PCI did not improve clinical outcomes overall. Whether improved methods for thrombus aspiration could reduce the risk of stroke and enhance overall benefit is not known, and warrants testing in future trials among patients with high thrombus burden.
possible for this outcome. Outcomes in the TASTE trial were from administrativ ive e e da da d ta ta taba ba base se es s s, clinical registries and death certificates and were not adjudicated. Another limitation is that hrombus g grade was assessed prior to wire crossing in both TAPAS and TOTAL and after wire cros ssi si sing in TA A AS S STE. E E Th Th Ther er e e wa wa was s s no no no adj djus u tmen n nt t fo or r mu u ult lt ltip ip iple le le c com m mpa pa pari riso ons n so o o al al all l l se se second nd dar ar ary y y anal al aly ys y es shoul ld d d be e con ns sidere re red hypothe esi is gener er e atin ing. . An An Anot o othe h her r limi mitation on i i is that no o a adju justmen nt fo 
TASTE
Procedurerelated stroke or neurologic complication as judged by the treating physician or in the ward.
Defined according to the Academic Research Consortium definition for "definite and confirmed stent thrombosis" i.e.: "symptoms suggestive of an acute coronary syndrome and angiographic or pathologic confirmation of stent thrombosis". In TASTE the diagnosis of stent thrombosis was confirmed by angiography in all cases.
A new therapeutic PCI in the same coronary artery as the index procedure or coronary artery bypass surgery after the index procedure.
TAPAS
No stroke or TIA collected.
Angiographically proven stent thrombosis was defined as a complete or partial occlusion within the stented segment, with evidence of thrombus and reduced Stroke/TIA at 30 Days
